News

Vinay Prasad, who headed the U.S. FDA division in charge of vaccines and was also chief medical and scientific officer, has ...
HHS Secretary RFK Jr. faces a probe launched by Democratic Senators over his decision to dismantle a key CDC vaccine advisory ...
HHS Secretary RFK Jr. vows to reform the Vaccine Injury Program, highlighting inefficiencies and favoritism in compensating ...
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax's H5N1 avian pandemic influenza vaccine candidate demonstrates immunogenicity in preclinical study: Gaithersburg, Maryland Friday, July 25, 2025, 15:00 Hrs [IST] Novavax, ...
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...
Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration ...
Novavax Inc. closed 59.74% below its 52-week high of $17.81, which the company achieved on July 26th.
Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.